Platelet function testing : Current practice among clinical centres in Northern Europe

Show full item record



Permalink

http://hdl.handle.net/10138/346639

Citation

Nordic Haemophilia Council , Szanto , T , Zetterberg , E , Ramström , S , Kärkkäinen , S & Lassila , R 2022 , ' Platelet function testing : Current practice among clinical centres in Northern Europe ' , Haemophilia , vol. 28 , no. 4 , pp. 642-648 . https://doi.org/10.1111/hae.14578

Title: Platelet function testing : Current practice among clinical centres in Northern Europe
Author: Nordic Haemophilia Council; Szanto, Timea; Zetterberg, Eva; Ramström, Sofia; Kärkkäinen, Satu; Lassila, Riitta
Contributor organization: Clinicum
University of Helsinki
HUS Comprehensive Cancer Center
Hematologian yksikkö
Research Program in Systems Oncology
Department of Oncology
Date: 2022-07
Language: eng
Number of pages: 7
Belongs to series: Haemophilia
ISSN: 1351-8216
DOI: https://doi.org/10.1111/hae.14578
URI: http://hdl.handle.net/10138/346639
Abstract: Introduction Platelet function tests are used to screen and diagnose patients with possible inherited platelet function defects (IPFD). Some acquired platelet dysfunction may be caused by certain drugs or comorbidities, which need to be excluded before testing. Aims To identify current practice among centres performing platelet function tests in Northern Europe. Methods A total of 14 clinical centres from Sweden (six), Finland (two), Denmark (two), Norway (one), Estonia (two) and Iceland (one) completed the survey questionnaire, the population capture area of about 29.5 million. Results Six of the 14 (42.8%) centres providing platelet function assessment represent comprehensive treatment centres (EUHANET status). A Bleeding score (BS) or ISTH bleeding assessment tool (ISTH BAT score) is evaluated in 11/14 (78.6%) centres and family history in all. Five/14 centres (35.7%) use structured preanalytical patient instructions, and 10/14 (71.4%) recorded questionnaire on the preassessment of avoidance of any drugs or natural products affecting platelet functions. Preliminary investigations of screening tests of coagulation are performed in 10/14 (71.4%), while in 4/14 (28.6%), the diagnostic work-up of IPFD and von Willebrand disease (VWD) is performed simultaneously. The work-up of IPFD includes peripheral blood smear in 10/14 (71.4%), platelet aggregometry in all, flow cytometry in 10/14 (71.4%) and Platelet Function Analysis (PFA) in 3/11 (28.6%). Molecular genetic diagnosis is available in 7/14 (50%) centres. Conclusions The considerable variability in the current practice illustrates the need for harmonization between the Northern European centres according to the international registers (i.e. EUHASS) and IPFD guidelines (ISTH, EHA).
Subject: blood platelet disorders
data collection
platelet function testing
platelets
survey
BLEEDING ASSESSMENT-TOOL
DISORDERS
DIAGNOSIS
COMMUNICATION
SUBCOMMITTEE
AGGREGOMETRY
SSC
Peer reviewed: Yes
Rights: cc_by_nc
Usage restriction: openAccess
Self-archived version: publishedVersion


Files in this item

Total number of downloads: Loading...

Files Size Format View
Haemophilia_202 ... res_in_Northern_Europe.pdf 511.9Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record